176 related articles for article (PubMed ID: 1413183)
1. [Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs].
Pedersen FM; Hamberg O; Sørensen MD; Neland K
Ugeskr Laeger; 1992 Sep; 154(38):2561-3. PubMed ID: 1413183
[TBL] [Abstract][Full Text] [Related]
2. Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency.
Rehn D; Golden G; Nocker W; Diebschlag W; Lehmacher W
Arzneimittelforschung; 1993 Oct; 43(10):1060-3. PubMed ID: 8267669
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings.
Unkauf M; Rehn D; Klinger J; de la Motte S; Grossmann K
Arzneimittelforschung; 1996 May; 46(5):478-82. PubMed ID: 8737630
[TBL] [Abstract][Full Text] [Related]
5. [Venoruton in chronic venous insufficiency].
Golden GJ
Ugeskr Laeger; 1993 Jan; 155(3):182-3. PubMed ID: 8421882
[No Abstract] [Full Text] [Related]
6. Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study.
Cesarone MR; Belcaro G; Ippolito E; Pellegrini L; Ledda A; Luzzi R; Ricci A; Dugall M; Bavera P; Hosoi M; Stuard S; Corsi M
Panminerva Med; 2010 Jun; 52(2 Suppl 1):43-8. PubMed ID: 20657534
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and safety of hydroxyethyl-rutosides in the local treatment of symptoms of venous insufficiency during air travel].
Gouny AM; Horovitz D; Gouny P; Sauvage E; Nussaume O
J Mal Vasc; 1999 Jun; 24(3):214-20. PubMed ID: 10467532
[TBL] [Abstract][Full Text] [Related]
8. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study.
Ippolito E; Belcaro G; Dugall M; Cesarone MR; Feragalli B; Errichi BM; Gizzi G; Pellegrini L; Ledda A; Luzzi R; Ricci A; Bavera P; Hosoi M; Corsi M; Errichi S
Panminerva Med; 2011 Sep; 53(3 Suppl 1):13-9. PubMed ID: 22108472
[TBL] [Abstract][Full Text] [Related]
9. Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study.
Petruzzellis V; Troccoli T; Candiani C; Guarisco R; Lospalluti M; Belcaro G; Dugall M
Angiology; 2002; 53(3):257-63. PubMed ID: 12025912
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency.
Rehn D; Unkauf M; Klein P; Jost V; Lücker PW
Arzneimittelforschung; 1996 May; 46(5):483-7. PubMed ID: 8737631
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the therapeutic equivalence of different galenical preparations of O-(beta-hydroxyethyl)-rutosides following multiple dose peroral administration.
Rehn D; Brunnauer H; Diebschlag W; Lehmacher W
Arzneimittelforschung; 1996 May; 46(5):488-92. PubMed ID: 8737632
[TBL] [Abstract][Full Text] [Related]
12. HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial.
Belcaro G; Cesarone MR; Bavera P; Ricci A; Renton S; Leon M; Ippolito E; Dugall M; Acerbi G
J Cardiovasc Pharmacol Ther; 2002 Jul; 7(3):139-45. PubMed ID: 12232562
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
Carpentier PH; Mathieu M
J Mal Vasc; 1998 Apr; 23(2):106-12. PubMed ID: 9608923
[TBL] [Abstract][Full Text] [Related]
14. An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency.
Beltramino R; Penenory A; Buceta AM
Int Angiol; 1999 Dec; 18(4):337-42. PubMed ID: 10811525
[TBL] [Abstract][Full Text] [Related]
15. [Placebo controlled efficacy of class 1 elastic stockings in chronic venous insufficiency of the lower limbs].
Vayssairat M; Ziani E; Houot B
J Mal Vasc; 2000 Oct; 25(4):256-62. PubMed ID: 11060420
[TBL] [Abstract][Full Text] [Related]
16. A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency.
Bergqvist D; Hallböök T; Lindblad B; Lindhagen A
Vasa; 1981; 10(3):253-60. PubMed ID: 7025500
[No Abstract] [Full Text] [Related]
17. [Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients].
Balmer A; Limoni C
Vasa; 1980; 9(1):76-82. PubMed ID: 7368843
[No Abstract] [Full Text] [Related]
18. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements.
Belcaro G; Rulo A; Candiani C
Vasa; 1989; 18(2):146-51. PubMed ID: 2662674
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers.
Kienzler JL; Sallin D; Schifflers MH; Ghika A
Eur J Clin Pharmacol; 2002 Sep; 58(6):395-402. PubMed ID: 12242598
[TBL] [Abstract][Full Text] [Related]
20. [Dosage of O-beta hydroxyethylrutoside in chronic venous insufficiency].
Stemmer R; Furderer CR
Phlebologie; 1986; 39(4):995-1003. PubMed ID: 3562569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
